{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:20:02Z","timestamp":1778620802849,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["TP-9356"],"award-info":[{"award-number":["TP-9356"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["IR.PII.REC.1401.015"],"award-info":[{"award-number":["IR.PII.REC.1401.015"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.intimp.2025.114032","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T07:46:02Z","timestamp":1737272762000},"page":"114032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["HeterologousPrime-Boost immunizationwithAdenoviral vector and recombinant subunit vaccines strategies against dengue virus type2"],"prefix":"10.1016","volume":"148","author":[{"given":"Mohammad","family":"Shoushtari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Salehi-Vaziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Kadkhodazadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Teimoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Arashkia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Roohvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Teimoori-Toolabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-1517","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Pouriayevali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-9043","authenticated-orcid":false,"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114032_b0005","doi-asserted-by":"crossref","unstructured":"L. L\u00e1zaro, D. Winter, K. Toancha, A. Borges, A. Gon\u00e7alves, A. Santos, M. do Nascimento, N. Teixeira, Y.S. Sequeira, A.K. Lima, Phylogenomics of Dengue Virus Isolates Causing Dengue Outbreak, S\u00e3o Tom\u00e9 and Pr\u00edncipe, 2022, Emerging Infectious Diseases 30(2) (2024).","DOI":"10.3201\/eid3002.231316"},{"key":"10.1016\/j.intimp.2025.114032_b0010","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s10529-021-03175-1","article-title":"Taguchi array optimization of the reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for sensitive and rapid detection of dengue virus serotype 2","volume":"43","author":"Shoushtari","year":"2021","journal-title":"Biotechnol. Lett"},{"key":"10.1016\/j.intimp.2025.114032_b0015","first-page":"1","article-title":"Structure-based evaluation of the envelope domain III\u2013nonstructural protein 1 (EDIII-NS1) fusion as a dengue virus vaccine candidate","author":"Shoushtari","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0020","article-title":"Neurological Complications in Dengue Among Males of the Adult Age Group","volume":"16","author":"Kakde","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.intimp.2025.114032_b0025","first-page":"397","article-title":"Emergence of Mosquito-borne Viruses in Iran and Adjacent Countries: The Case of Chikungunya","volume":"11","author":"Bakhshi","year":"2023","journal-title":"Journal of Health Sciences & Surveillance System"},{"issue":"3","key":"10.1016\/j.intimp.2025.114032_b0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue vaccines: An update","volume":"36","author":"Torres-Flores","year":"2022","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.intimp.2025.114032_b0035","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.114032_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1200195","article-title":"Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement","volume":"14","author":"Sarker","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114032_b0045","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001831","article-title":"Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114032_b0050","first-page":"836","article-title":"Dengue virus type-3 envelope protein domain III; expression and immunogenicity","volume":"17","author":"Fahimi","year":"2014","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"23","key":"10.1016\/j.intimp.2025.114032_b0055","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Jaiswal","year":"2003","journal-title":"J. Virol."},{"issue":"30","key":"10.1016\/j.intimp.2025.114032_b0060","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.vaccine.2016.03.108","article-title":"Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold\/DNA vaccine in non-human primates","volume":"34","author":"McBurney","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2025.114032_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2022.101818","article-title":"Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains","volume":"63","author":"Shoushtari","year":"2022","journal-title":"Mol. Cell. Probes"},{"issue":"6","key":"10.1016\/j.intimp.2025.114032_b0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-023-00938-y","article-title":"Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement","volume":"30","author":"Yen","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"23","key":"10.1016\/j.intimp.2025.114032_b0080","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1128\/JVI.00871-13","article-title":"High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0085","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1038\/s41467-018-07667-z","article-title":"Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection","volume":"9","author":"Jayathilaka","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.114032_b0090","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/vaccines9060622","article-title":"Flavivirus NS1 and its potential in vaccine development","volume":"9","author":"Carpio","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.intimp.2025.114032_b0095","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b7 5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob. Health"},{"issue":"11","key":"10.1016\/j.intimp.2025.114032_b0100","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/vaccines10111940","article-title":"Preparedness for the dengue epidemic: vaccine as a Viable approach","volume":"10","author":"Zeyaullah","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2025.114032_b0105","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent developments in recombinant protein\u2013based dengue vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114032_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","author":"Manoff","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2025.114032_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128784","article-title":"Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice","volume":"14","author":"Aggarwal","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114032_b0120","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ymthe.2022.01.034","article-title":"Adenovirus-based vaccines\u2013a platform for pandemic preparedness against emerging viral pathogens","author":"Coughlan","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2025.114032_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.intimp.2025.114032_b0130","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/genes13111941","article-title":"Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics","volume":"13","author":"Farhad","year":"2022","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.intimp.2025.114032_b0135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/vaccines11020432","article-title":"Adenoviral vector-based vaccine platform for COVID-19: Current status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.intimp.2025.114032_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2079323","article-title":"Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses","volume":"18","author":"Shoushtari","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.114032_b0150","first-page":"1054","article-title":"Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice","volume":"17","author":"Fahimi","year":"2018","journal-title":"EXCLI J."},{"issue":"15","key":"10.1016\/j.intimp.2025.114032_b0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00581-19","article-title":"Infection of Aedes albopictus mosquito C6\/36 cells with the w Melpop strain of Wolbachia modulates dengue virus-Induced host cellular transcripts and induces critical sequence alterations in the dengue viral genome","volume":"93","author":"Teramoto","year":"2019","journal-title":"J. Virol."},{"issue":"43","key":"10.1016\/j.intimp.2025.114032_b0160","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2009.07.073","article-title":"An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity","volume":"27","author":"Khanam","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2025.114032_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108132","article-title":"An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella","volume":"100","author":"Felegary","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114032_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240076","article-title":"Correlation of ELISA method with three other automated serological tests for the detection of anti-SARS-CoV-2 antibodies","volume":"15","author":"Nguyen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.114032_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840104","article-title":"Current development and challenges of tetravalent live-attenuated dengue vaccines","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114032_b0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114032_b0185","first-page":"849","article-title":"Dengue virus: molecular basis of cell entry and pathogenesis, 25\u201327 June 2003","volume":"23","author":"Halstead","year":"2005","journal-title":"Vienna, Austria, Vaccine"},{"key":"10.1016\/j.intimp.2025.114032_b0190","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fimmu.2018.00597","article-title":"Modulation of dengue\/zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in zika virus infection","volume":"9","author":"Khandia","year":"2018","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2025.114032_b0195","doi-asserted-by":"crossref","first-page":"11403","DOI":"10.1128\/JVI.79.17.11403-11411.2005","article-title":"The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity","volume":"79","author":"Alcon-LePoder","year":"2005","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114032_b0200","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1096\/fj.99-0829com","article-title":"Dengue virus nonstructural protein 1 is expressed in a glycosyl\u2010phosphatidylinositol\u2010linked form that is capable of signal transduction","volume":"14","author":"Jacobs","year":"2000","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.intimp.2025.114032_b0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.00276-11","article-title":"Complement-mediated neutralization of dengue virus requires mannose-binding lectin","volume":"2","author":"Avirutnan","year":"2011","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0210","doi-asserted-by":"crossref","first-page":"12933","DOI":"10.1038\/s41598-020-69515-9","article-title":"Peptides targeting dengue viral nonstructural protein 1 inhibit dengue virus production","volume":"10","author":"Songprakhon","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2025.114032_b0215","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4049\/jimmunol.1900136","article-title":"Combination of modified NS1 and NS3 as a novel vaccine strategy against dengue virus infection","volume":"203","author":"Kao","year":"2019","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114032_b0220","doi-asserted-by":"crossref","first-page":"e2330","DOI":"10.1371\/journal.pntd.0002330","article-title":"Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge","volume":"7","author":"Henriques","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.114032_b0225","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/vaccines10122028","article-title":"Unbiased Identification of Dengue Virus Non-Structural Protein 1 Peptides for Use in Vaccine Design","volume":"10","author":"Warner","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2025.114032_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-018-0462-0","article-title":"Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate","volume":"25","author":"Chen","year":"2018","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.114032_b0235","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime\u2013boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114032_b0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2025.114032_b0245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/aid.1991.7.615","article-title":"Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160","volume":"7","author":"Hu","year":"1991","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.intimp.2025.114032_b0250","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"5043","key":"10.1016\/j.intimp.2025.114032_b0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.1531159","article-title":"Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160","volume":"255","author":"Hu","year":"1992","journal-title":"Science"},{"issue":"45","key":"10.1016\/j.intimp.2025.114032_b0260","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.vaccine.2022.09.007","article-title":"\u2018Mix and Match\u2019vaccination: Is dengue next?","volume":"40","author":"Odio","year":"2022","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2025.114032_b0265","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the E protein of dengue virus type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw."},{"issue":"37","key":"10.1016\/j.intimp.2025.114032_b0270","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1016\/j.vaccine.2011.06.085","article-title":"Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review","volume":"29","author":"Girard","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2025.114032_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022011","article-title":"Subdominant\/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite","volume":"6","author":"Dominguez","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-016-0302-z","article-title":"Differential humoral and cellular immunity induced by vaccination using plasmid DNA and protein recombinant expressing the NS3 protein of dengue virus type 3","volume":"23","author":"Hurtado-Melgoza","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114032_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-8-86","article-title":"Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity","volume":"8","author":"Bozza","year":"2008","journal-title":"BMC Infect. Dis."},{"issue":"7258","key":"10.1016\/j.intimp.2025.114032_b0290","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 responses: what are they?","volume":"321","author":"Berger","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2025.114032_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2025.114032_b0300","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169251","article-title":"NKT cells promote Th1 immune bias to dengue virus that governs long-term protective antibody dynamics","volume":"134","author":"Choi","year":"2024","journal-title":"J. Clin. Invest."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:58:14Z","timestamp":1778619494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":60,"alternative-id":["S1567576925000219"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114032","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HeterologousPrime-Boost immunizationwithAdenoviral vector and recombinant subunit vaccines strategies against dengue virus type2","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114032"}}